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Phosphoglycerate mutase (PGM) (D-Phosphoglycerate 2,3-
phosphomutase, EC 5.4.2.1), and enolase (2-phospho-D-glycerate
hydrolyase, EC 4.2.1.11) are glycolytic enzymes that catalyse
consecutive reversible reactions connecting the two ATP-gener-
ating reactions in the glycolytic pathway. PGM catalyses the
conversion of 3-phosphoglycerate, product of the first ATP-gener-
ating reaction, into 2-phosphoglycerate, in the presence of the co-
factor 2,3-bisphosphoglycerate. In addition to the main mutase
activity, PGM possesses collateral 2,3-bisphosphoglycerate phos-
phatase (BPGP; EC 3.1.3.13) activity which is stimulated by 2-
phosphoglycolate (reviewed in Fothergill-Gilmore and Watson,
1989). Enolase catalyses the conversion of 2-phosphoglycerate
into phosphoenolpyruvate, substrate of the second ATP-generating
glycolytic reaction (reviewed in Wold, 1971). Creatine kinase
(CK) (ATP: creatine N-phosphotransferase, EC 2.7.3.2) is an ubiq-
uitous enzyme that catalyses the reversible transphosphorylation
reaction between ATP and creatine, generating ADP and phospho-
creatine. It has a key role in the energy metabolism of cells with
high and fluctuating energy demands, where it develops two main
primary functions: to constitute a temporal energy buffer and a
spatial energy buffer or energy transport system between intracel-
lular sites of ATP production and sites of ATP consumption. In
addition, CK develops other secondary functions: to prevent a rise
in intracellular ADP avoiding an inactivation of ATPases, to avoid
oscillations in the concentration of high-energy phosphates upon
abrupt changes in workload, to provide appropriate local
ATP/ADP ratios at subcellullar sites and to act as proton buffering
system (reviewed in Walliman et al, 1992; Wyss et al, 1992).
All these enzymes possess tissue-specific isoenzymes. In
mammalian tissues, there are three isoenzymes of PGM and three
cytosolic isoenzymes of CK which result, in both cases, from the
homodimeric and the heterodimeric combinations of two different
subunits coded by separate genes and designated M (muscle) and
B (brain). In early fetal life, type BB-PGM and type BB-CK are
the only present forms. During myogenesis the isoenzyme pheno-
types undergo transition, type BB-PGM and type BB-CK being
replaced by the MM forms through the MB isoenzymes. In adult
mammals, skeletal muscle contain almost exclusively type MM-
PGM and type MM-CK, whereas type BB-PGM and type BB-CK
are found in most other tissues. Only in heart are the three PGM
and CK isoenzymes present in substantial amounts. In addition to
the cytosolic CK subunits, mammalian tissues express two mito-
chondrial CK subunits (‘ubiquitous’ Mt-CK and ‘sarcomeric’
Mt-CK subunits) that form octameric and dimeric molecules
(reviewed in Wallimann et al, 1992; Wyss et al, 1992; Carreras and
Gallego, 1993; Durany and Carreras, 1996). In addition to PGM
isoenzymes, in mammalian tissues there are other enzymes that
have 2-phosphoglycolate-stimulated BPGP activity. One of them
is the 2,3-bisphosphoglycerate synthase-phosphatase or 2,3-
bisphosphoglycerate mutase (BPGM; EC 5.4.2.4), which is a
homodimer of a subunit that possesses great homology with PGM
subunits. Two other enzymes are heterodimers resulting from the
combination of a BPGM subunit with a PGM subunit either type
M or type B (reviewed in Carreras and Gallego, 1993). Enolase
molecules are dimers composed of three distinct subunits coded by
separate genes and designated a(liver), b(muscle) and g(brain).
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The  aa isoenzyme exists in all fetal tissues and most adult
mammalian tissues. bb- and gb-enolase are found predominantly
in skeletal and heart muscle. gg- and ag-enolase are present mainly
in nervous tissue and in tissues with neuroendocrine cells. They
have been frequently designated as neuron-specific enolase (NSE)
(Schmechel et al, 1978; Kato et al, 1983; Haimoto et al, 1985).
As a first step to investigate the alterations of the expression of
the enzymes of energy metabolism in neoplastic tissues, in order to
explain the underlying metabolic changes and to validate tumour
marker enzymes and prognostic factors, we have studied the distri-
bution of PGM, enolase, cytosolic CK and BPGP activities and
isoenzymes in several human tumours. There is a wealth of infor-
mation concerning the expression of CK and enolase activity and
isoenzymes in neoplastic tissues. However, most data have been
obtained by inmunohistochemical and inmunoassay techniques,
and only a few reports have been published on the distribution of
CK (reviewed in Foreback and Chu, 1981; Bais and Edwards,
1982; Griffiths, 1982; Nanji, 1983; Kanemitsu and Okigaki, 1984)
and enolase isoenzyme proteins in tumours (reviewed in Taylor et
al, 1983; Royds et al, 1985; Schmechel, 1985; Gerbitz et al, 1986;
Marangos and Schmechel, 1987; Kaiser et al, 1989). Concerning
the distribution of PGM isoenzymes in neoplastic tissues, only
some data on brain tumours were available (Omenn and Cheung,
1974; Omenn and Hermodson, 1975). We have already published
data concerning brain, lung, colon and liver tumours (Joseph et al,
1996, 1997; Durany et al, 1997a, 1997b). In the present study we
present the results concerning normal breast and breast carci-
nomas, which largely confirm the findings from the other cancer
types.
MATERIALS AND METHODS
Materials
Enzymes, substrates, co-factors and biochemicals were purchased
from either Boehringer (Mannheim, Germany) or Sigma (St Louis,
MO, USA). b-Mercaptoethanol was from Merck (Darmstadt,
Germany) and bovine serum albumin was from Calbiochem (La
Jolla, CA, USA). Other chemicals were reagent grade. Agar noble
was obtained from Difco Laboratories (Detroit, MI, USA).
Cellulose acetate strips were from Helena Laboratories
(Beaumont, TX, USA) and agarose gels were from Ciba-Corning
(Palo Alto, CA, USA).
Tissue samples
Twenty-five breast carcinoma specimens were obtained from
surgical resection. In 12 cases samples were available from non-
neoplastic areas of the tissue. Samples were snap-frozen in liquid
nitrogen and stored at –80°C. The specimens were provided by the
Tissue Bank and by the Hormonal Laboratory of the Hospital Clínic
i Provincial, with the approval of the Hospital Ethics Committee.
Tissue extraction
Tissue extracts were prepared by homogenization in 3 vol (w/v) of
cold 20 mM Tris–HCl buffer, pH 7.5, containing 1 mM EDTA and
1m M b-mercaptoethanol with a Polytron homogenizer (Luzern,
Switzerland) (position 5, 20 s). Cellular debris were removed by
centrifugation at 4°C for 30 min at 12 500 g and the supernatants
were used for the assay of enzyme activities and isoenzymes.
Enzyme and protein assays
PGM, BPGP, CK and enolase activities were determined as previ-
ously described (Durany and Carreras, 1996; Joseph et al, 1996,
1997). Enzyme activities were expressed as U g–1 wet tissue and as
U mg–1 protein (1 Unit = 1 mmol substrate converted per min).
Protein was determined by the method of Bradford (1976), using
bovine serum albumin as a standard.
Isoenzyme analysis
The methods previously described were used to evaluate PGM
isoenzymes by cellulose acetate electrophoresis (Durany and
Carreras, 1996) and CK and enolase isoenzymes by agarose gel
electrophoresis (Joseph et al, 1996, 1997).
Table 1 Levels of PGM activity in breast normal tissue and carcinomas
Normal tissue Tumour tissue
Case no. U g–1 U mg–1 U g–1 U mg–1
1 2.4 0.18 3.9 0.24
2 1.8 0.15 6.0 0.46
3 2.1 0.19 8.9 0.36
4 5.7 0.30 15.9 0.80
5 1.8 0.08 16.8 0.65
6 0.5 0.03 4.2 0.33
7 0.6 0.05 6.8 0.50
8 0.8 0.04 9.6 0.48
9 1.0 0.05 9.6 0.38
10 0.5 0.03 3.9 0.20
11 0.5 0.05 3.4 0.23
12 0.4 0.04 3.1 0.23
Mean ± s.e.m. 1.5 ± 0.4 0.1 ± 0.02 7.6 ± 1.3 0.4 ± 0.05
Median (range) 0.9 (0.4–5.7) 0.05 (0.03–0.3) 6.4 (3.1–16.8) 0.37 (0.2–0.8)
The activity is expressed as units per g wet tissue and as units per mg of
extracted protein. The comparisons are as follows: U g–1: control vs
carcinoma, P < 0.0005; U mg–1: control vs carcinoma, P < 0.0005.
Table 2 Levels of creatine kinase activity in breast normal tissue and
carcinomas
Normal tissue Tumour tissue
Case no. U g–1 U mg–1 U g–1 U mg–1
1 2.10 0.16 0.60 0.04
2 1.50 0.12 0.92 0.06
3 1.60 0.14 3.86 0.09
4 3.50 0.16 2.20 0.10
5 0.85 0.03 1.20 0.04
6 2.40 0.16 8.06 0.37
7 0.88 0.07 0.60 0.04
8 1.90 0.07 1.12 0.04
9 2.00 0.09 6.10 0.19
10 1.30 0.07 3.10 0.18
11 0.84 0.09 2.30 0.13
12 1.41 0.07 3.70 0.26
Mean ± s.e.m. 1.7 ± 0.2 0.1 ± 0.01 2.8 ± 0.67 0.12 ± 0.03
Median (range) 1.6 0.09 2.2 0.09
(0.84–3.5) (0.03–0.16) (0.6–8.06) (0.04–0.37)
The activity is expressed as units per g wet tissue and as units per mg of
extracted protein. The comparisons are as follows: U g–1: control vs
carcinoma, non-significant; U mg–1: control vs carcinoma, non-significant.22 N Durany et al
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Inhibition of M-CK subunit
Inhibition of M-CK subunit by M-CK antibodies was performed as
previously described (Joseph et al, 1997).
Oestrogen and progesterone receptor analysis
Oestrogen receptor (ER) and progesterone receptor (PR) were
immunohistochemically analysed by the stretavidin–biotin–alka-
line phosphatase method as previously reported (Jares et al, 1997).
Cases were evaluated with a modified HSCORE system (McCarty
et al, 1985) by multiplying the stratified percentage of positive
cells (1–33% = 1; 34–66% = 2; 67–100% = 3) by the average
intensity of each case (1 to 3). A case was considered R-positive
when the score was 1 or higher. Normal glands and ducts were
used as internal positive controls. As a negative control, primary
antibodies were replaced by unrelated monoclonal antibodies and
by phosphate-buffered saline (PBS).
Statistical analysis
For statistical evaluation, the Wilcoxon T-test was used to
compare enzyme activities in tumour and control tissue. The
Kruskal–Wallis test (non-parametric analysis of variance) was
employed to compare enzyme activity levels among different
tumour groups and control. The differences between groups were
located using the Mann–Whitney U-test. All P-values are two-
tailed. Values are reported as mean ± s.e.m. and as median and
range. Data were analysed by Instat statistical software.
RESULTS AND DISCUSSION
Distribution of PGM, CK, enolase and BPGP activities
Tables 1–4 summarize the levels of total PGM, CK, enolase and
BPGP activities in breast normal tissue and tumours. Figures 1–3
present some of the isoenzyme patterns determined by elec-
trophoresis, and Tables 5 and 6 summarize the distribution of the
isoenzymes in normal and tumour tissues. Opinions differ widely
as to how is the most useful way to express the enzyme activity in
tissue when diverse tissues are being compared (Crabtree et al,
1979). Changes in tissue structure, in the proportion of
parenchymal cells and in the active metabolic mass of tissue in
tumours could mask the intracellular levels of enzyme activity
when the activity is expressed as a function of the wet tissue mass.
Changes in the total amount of extractable protein resulting from
the neoplastic transformation could mask the levels of enzyme
activity when it is expressed as a function of the extracted protein.
Therefore we have determined the enzyme activities as a function
of both wet tissue mass and extracted protein.
As shown, normal breast tissue possesses similar levels of
PGM, CK and enolase activities, and much lower levels of 2-phos-
phoglycolate-stimulated BPGP activity, which is in agreement
with the different functions of these enzymes. Whereas PGM and
enolase are enzymes of the main glycolytic pathway and CK is
directly involved in energy metabolism, BPGP participates in the
2,3-bisphosphoglycerate bypass (or Rapoport-Luebering shunt), a
collateral deviation of glycolysis (Rapoport, 1968).
Breast tumours have significantly higher PGM (Table 1) and
enolase (Table 3) activity levels than the corresponding normal
tissues, which agree with data reported on other glycolytic
enzymes. It was found that enolase, hexokinase, phosphofructo-
kinase, pyruvate kinase and aldolase activities were elevated in
breast carcinoma in comparison to benign breast diseases and
normal breast tissue, although great intratumoural and inter-
tumoural heterogeneity was observed (Hennipman et al, 1987,
1988).
It has been reported (Meyer et al, 1980; Tsung, 1983; Lakatua et
al, 1986) that the levels of CK activity in breast carcinoma are
higher than in normal breast tissue. As shown in Table 2, we have
found higher CK activity in only seven out of 12 cases. In one of
these cases (no. 3), CK activity in neoplastic tissue was lower than
in normal tissue when the activity was reported as a function of the
extracted protein. However, in this case the extracted protein from
the tumour tissue was abnormally high (3.6-fold that of the normal
tissue). In all other cases, although the extracted protein from
tumoural tissue was higher than the extracted protein from normal
Table 3 Levels of enolase activity in breast normal tissue and carcinomas
Normal tissue Tumour tissue
Case no. U g–1 U mg–1 U g–1 U mg–1
1 0.95 0.07 1.6 0.10
2 1.10 0.09 4.5 0.29
3 1.10 0.10 10.0 0.26
4 8.30 0.38 7.4 0.36
5 0.90 0.04 3.3 0.10
6 1.03 0.07 4.4 0.20
7 0.62 0.05 3.7 0.27
8 1.99 0.07 2.7 0.10
9 3.30 0.16 14.8 0.47
10 1.25 0.07 4.7 0.27
11 0.71 0.07 4.6 0.25
12 1.26 0.06 4.4 0.32
Mean ± s.e.m. 1.9 ± 0.6 0.1 ± 0.026 5.51 ± 1.05 0.25 ± 0.03
Median (range) 1.1 0.07 4.5 0.26
(0.6–8.3) (0.04–0.38) (1.6–14.8) (0.1–0.47)
The activity is expressed as units per g wet tissue and as units per mg of
extracted protein. The comparisons are as follows: U g–1: control vs
carcinoma, P < 0.002; U mg–1: control vs carcinoma, P < 0.001.
Table 4 Levels of BPGP activity in breast normal tissue and carcinomas
Normal tissue Tumour tissue
Case no. mU g–1 mU mg–1 mU g–1 mU mg–1
1 60.5 4.5 50.1 3.2
2 57.0 4.2 39.9 3.1
3 63.0 5.7 54.0 2.2
4 83.2 4.4 55.1 2.8
5 79.9 3.6 60.1 2.4
6 64.8 4.3 39.9 3.1
7 14.9 1.3 10.2 0.8
8 117.0 5.5 27.3 1.3
9 93.0 5.0 64.8 2.6
10 32.4 2.2 24.9 1.5
11 74.7 8.0 71.4 4.8
12 19.8 2.1 12.3 1.2
Mean ± s.e.m. 63 ± 8.6 4.2 ± 0.5 42.5 ± 5.8 2.4 ± 0.3
Median (range) 63 (15–117) 4.3 (1.3–8.0) 45 (10–71) 2.5 (0.8–4.8)
The activity is expressed as units per g wet tissue and as units per mg of
extracted protein. The comparisons are as follows: U g–1: control vs
carcinoma, P < 0.0005; U mg–1: control vs carcinoma, P < 0.0015.PGM, BPGP, CK and enolase in breast carcinoma 23
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tissue, it did not surmount a 1.5-fold increase.
In contrast to PGM, enolase and CK, the levels of 2-phospho-
glycolate-stimulated BPGP activity in breast tumours are lower
than in normal breast tissue (Table 4). The fact that breast carci-
nomas present opposite changes in the levels of PGM activity and
of 2-phosphoglycolate-stimulated BPGP activity indicates that in
tumoural tissue change both the concentration of PGM and the
concentration of the other enzymes that also have BPGP activity
(BPGM and BPGM-PGM hybrid). Similar results have been
found in lung, colon and liver carcinomas (Durany et al, 1997),
which indicates that in all these tumours could decrease the meta-
bolic flux through the 2,3-bisphosphoglycerate shunt, and change
the intracellular concentration of 2,3-bisphosphoglycerate. It is
known that this metabolite, in addition to act as cofactor of PGM,
‘in vitro’ inhibits several enzymes involved in the carbohydrate
and adenine nucleotide metabolism, although the physiological
significance of these inhibitory effects is uncertain (reviewed in
Carreras et al, 1986).
Distribution of PGM, CK and enolase isoenzymes
No previous data exist on the distribution of PGM isoenzymes in
breast normal tissue and tumours. Our results (Table 5 and Figure
1) show that in normal breast tissue type BB-PGM is the major
PGM isoenzyme. Type MB-PGM is present in very small propor-
tion (mean value: 4% of the total PGM activity) and type MM-
PGM is generally not detected. In breast carcinomas a decrease of
PGM isoenzymes possessing M-type subunit is observed: in most
speciments of breast tumours only type BB-PGM is detected. As
indicated in the Introduction, in mammals, type B subunit is the
only PGM subunit expressed in early fetal life. During develop-
ment, in muscle, brain and sperm cells a switch from type B to
type M PGM subunit occurs, but only in skeletal muscle and
sperm cells a complete transition takes place. As a consequence, in
adult mammals, skeletal muscle and sperm cells contain almost
exclusively type MM-PGM, whereas in heart and in some brain
areas, types MB and BB-PGM are present in substantial amounts.
Table 5 Distribution of PGM isoenzymes in breast normal tissue and carcinomas
Normal tissue Tumour tissue
Case no. MM MB BB MM MB BB
1 1 11 88 0 0 100
2 0 9 91 0 0 100
3 0 0 100 0 2 98
4 0 4 96 0 0 100
5 0 0 100 0 0 100
6 0 2 98 0 0 100
7 049 6 0 19 9
8 0 2 98 0 0 100
9 0 4 96 0 0 100
10 0 3 97 0 0 100
11 0 9 91 0 0 100
12 0 0 100 0 0 100
Mean ± s.e.m. 0.08 ± 0.08 4 ± 1.0 95.9 ± 1.1 0 ± 0 0.25 ± 0.1 99.7 ± 0.1
Median (range) 0 (0–1) 3.5 (0–11) 96.5 (88–100) 0 (0–0) 0 (0–2) 100 (98–100)
The results are expressed as percentage of the total PGM activity on electrophoresis. No statistical significant differences were observed.
Table 6 Distribution of enolase isoenzymes in breast normal tissue and carcinomas
Normal tissue Tumour tissue
Case no. aa ag gg aa ag gg
1 86 12 2 76 20 1
28 9 9 2 8 2 1 5 3
39 0 9 1 6 7 2 9 4
4 83 16 1 81 18 1
5 88 12 0 90 10 0
6 85 13 2 54 35 11
79 7 2 1 8 5 1 3 2
8 83 14 3 79 18 3
9 85 13 2 81 16 3
10 89 10 1 84 15 1
11 90 10 0 88 11 1
12 86 13 1 80 18 2
Mean ± s.e.m. 87.5 ± 1.1 11.1 ± 1.0 1.3 ± 0.25 78.9 ± 2.8 18.1 ± 2.8 2.6 ± 0.8
Median (range) 87.0 (83–97) 12.0 (2–16) 1.0 (0–3) 81.0 (54–90) 17.0 (10–35) 2.0 (0–11)
The results are expressed as percentage of the total enolase activity on electrophoresis. The comparisons are as follows: aa-enolase: control
vs carcinoma, P < 0.0015; ag-enolase: control vs carcinoma, P < 0.0015; gg-enolase: control vs carcinoma, P < 0.05.24 N Durany et al
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The expression of type M-PGM subunit is almost null in the other
adult mammalian tissues, although in some of them the hybrid
type MB-PGM is detected in small proportion (Durany and
Carreras, 1996; Durany et al, 1997a, 1997b). Therefore, the
decrease in the expression of type M-PGM subunit in breast
neoplastic cells now reported can be interpreted as a return to a
more undifferentiated isoenzyme pattern. This fact probably does
not have any physiological meaning, since the proportion of PGM
isoenzymes containing type M subunit in normal breast tissue is
very low and all PGM isoenzymes possess similar kinetic proper-
ties (Bartrons and Carreras, 1982).
By immunoperoxidase staining (Wold et al, 1981) only type B-
CK subunit has been detected in normal breast ductal epithelium,
and by electrophoresis (Tsung, 1983) and ion-exchange chromatog-
raphy (Lakatua et al, 1986) it has been found that BB-CK was the
predominant CK isoenzyme present in normal breast tissue,
although MB- and MM-CK isoenzymes were found, at much lower
proportion, in some specimens. The CK isoenzyme pattern of
breast carcinomas, determined by electrophoresis (Tsung, 1983), by
ion-exchange chromatography (Kaye et al, 1981; 1986; Tsung,
1983; Lakatua et al, 1986; Scambia et al, 1986b) and by immuno-
reactivity (Zarghami et al, 1995) has been found to vary greatly
(from 100% BB-CK to 100% MM-CK), although most tumours
showed preponderance of the BB-CK form.
As shown in Figure 2, we have detected only type BB-CK in
most specimens of both normal and tumour breast tissue. Neither
MM-CK nor MB-CK were detected, but it has to be noted that
very low levels of CK (less than 5% of the total CK activity) would
not be detected in our electrophoretic analysis. In some cases, in
overloaded and overstained electrophoretograms, it was found a
cathodic band migrated as Mt-CK and was not affected by incuba-
tion with anti M-CK antibodies (not shown). Mt-CK is known to
strongly bind to the outer face of the inner mitochondrial
membrane. To be quantitatively detached requires phosphate
buffer, high molarity and high pH (Wiss et al, 1982). Our extrac-
tion procedure (low buffer strength, no salt, neutral pH) was
Table 7 CK, PGM, enolase and BPGP activities as a function of receptor status
Activity Tissue Receptor status No. U g–1 tissue U mg–1 protein
Mean ± s.e.m. Median (range) Mean ± s.e.m. Median (range)
CK Normal 12 1.70 ± 0.22 1.50 (0.84–3.5) 0.10 ± 0.013 0.09 (0.03–0.16)
Tumoural ER+ PR+ 12 2.32 ± 0.47 2.15 (0.6–6.7) 0.12 ± 0.026 0.085 (0.04–0.34)
Tumoural ER– PR– 10 1.93 ± 0.52 1.30 (0.6–6.1) 0.08 ± 0.018 0.064 (0.04–0.19)
PGM Normal 12 1.50 ± 0.43 0.90 (0.4–5.7) 0.10 ± 0.025 0.05 (0.03–0.30)
Tumoural ER+ PR+ 10 5.44 ± 1.02 3.85 (2.6–11.9) 0.26 ± 0.038 0.23 (0.10–0.46)
Tumoural ER– PR– 13 9.36 ± 1.18 9.60 (3.4–16.8) 0.43 ± 0.050 0.44 (0.18–0.80)
Enolase Normal 12 1.87 ± 0.62 1.10 (0.62–8.3) 0.10 ± 0.027 0.07 (0.04–0.38)
Tumoural ER+ PR+ 10 4.20 ± 0.60 4.45 (1.6–8.1) 0.20 ± 0.027 0.20 (0.09–0.32)
Tumoural ER– PR– 10 7.38 ± 1.36 6.33 (2.7–14.8) 0.32 ± 0.043 0.34 (0.10–0.47)
BPGP Normal 12 63.3 ± 8.61 64.0 (14.9–117) 4.23 ± 0.52 4.35 (1.30–8.0)
Tumoural ER+ PR+ 7 60.5 ± 11.08 63.0 (12.3–97) 3.24 ± 0.46 3.20 (1.20–4.8)
Tumoural ER– PR– 7 41.7 ± 7.86 50.0 (10.2–64.8) 2.00 ± 0.297 2.40 (0.80–2.80)
The comparisons are as follows. CK, U g–1: ER+PR+ vs normal, ER–PR– vs normal, and ER+PR+ vs ER–PR–, not significant. U mg–1: ER+PR+ vs normal,
ER–PR– vs normal, and ER+PR+ vs ER–PR–, not significant. PGM, U g–1: ER+PR+ vs normal, P < 0.0001; ER–PR– vs normal, P < 0.0001; ER+PR+ vs
ER–PR–, P < 0.05. U mg–1: ER+PR+ vs normal, P < 0.05; ER–PR– vs normal, P < 0.0001; ER+PR+ vs ER–PR–, P < 0.05. Enolase, U g–1: ER+PR+ vs normal,
P < 0.05; ER–PR– vs normal, P < 0.05; ER+PR+ vs ER– PR–, not significant. U mg–1: ER+PR+ vs normal, P < 0.05; ER–PR– vs normal, P < 0.05; ER+ PR+ vs
ER–PR–, P < 0.05. BPGP, mU g–1: ER+PR+ vs normal, ER–PR– vs normal, and ER+PR+ vs ER–PR– not significant. mU mg–1: ER–PR– vs normal, P < 0.05;
ER+PR+ vs normal and ER+PR+ vs ER–PR–, not significant.
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Figure 1 Electrophoretograms of PGM isoenzymes in extracts of human
breast normal tissue and carcinomas. Lanes 1 and 2, case no. 1; lanes 3 and
4, case no. 3; lanes 5 and 6, case no. 4; lanes 7 and 8, case no. 5. Uneven
lanes, tumour tissue; even lanes, normal tissue. Experimental conditions
were those described in Material and Methods
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Figure 2 Electrophoretograms of CK isoenzymes in extracts of human
breast normal tissue and carcinomas. Lane 1, heart; lane 8, brain; lanes 2
and 3, case no. 3; lanes 4 and 5, case no. 4; lanes 6 and 7, case no. 5. Even
lanes, tumour tissue; uneven lanes, normal tissue. Experimental conditions
were those described in Material and MethodsPGM, BPGP, CK and enolase in breast carcinoma 25
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selected to extract only the CK cytosolic isoenzymes but, as we
have previously verified (Durany et al, 1997b; Joseph et al, 1997),
it extracts also some Mt-CK.
Some of the conflicting results on the distribution of CK iso-
enzymes in breast could be explained by the confusion created by
adenylate kinase, Mt-CK or BB-CK. Adenylate kinase and Mt-CK
can contaminate the MM-CK electrophoretic band and by ion-
exchange chromatography co-elute with MM-CK (Klein and
Jeunelot, 1978; Lindsey et al, 1978; Desjardins, 1982; Urdal et al,
1983). From BB-CK may appear an artefactual band with an
electrophoretic mobility similar to that of MB-CK (Chastian et al,
1988). Moreover, by electrophoresis (Meyer et al, 1980) in breast
tumours a variant of CK-isoenzymes has been found which
migrated anodal to MM-CK. This variant, that was present only in
small quantities in normal breast tissue, was unaffected by anti-
bodies specific for both the M- and B-CK subunits (Meyer et al,
1980).
As shown in Figure 3 and summarized in Table 6, in normal
breast tissue aa-enolase is the predominant enolase isoenzyme.
ag-enolase is present in much lower proportion (2–16%) and the
levels of gg-enolase are very low (0–3%). Breast tumours possess a
distribution of enolase isoenzymes similar to that of normal tissue,
although the proportion of the isoenzymes possessing type g
subunit is higher. ag- and gg-enolase represent 8–35% and 0–11%
of the total enolase activity respectively. No additional correlation
is observed between activity changes and changes of the
isoenzyme pattern when single cases are analysed. These results
agree with data published by others. By cellulose acetate
electrophoresis,  aa-enolase was found to be the major enolase
isoenzyme in normal breast tissue and in breast carcinomas
(Hennipman et al, 1987). By ion-exchange chromatography NSE
was found to represent 4–10% of the total enolase activity in four
breast carcinomas (Pahlman et al, 1986). By immunohistochem-
istry no positive staining for g-enolase was found in normal breast
tissue (Vinores et al, 1984; Nesland et al, 1986b, 1987, 1988), but
a high proportion of g-enolase was detected in breast carcinoma
(Vinores et al, 1984; Haimoto et al, 1985; Nesland et al, 1985,
1986a, 1986b, 1988, 1991a, 1991b; Wilander et al, 1987; Erikstein
et al, 1988; Ingelman-Sundberg et al, 1989; Lilleng et al, 1992;
Scopsi et al, 1992; Matsushima et al, 1994). By radioimmunoassay
g-enolase was also detected in breast carcinoma cell lines (Reeve
et al, 1986; Zeltzer et al, 1986). We have previously found in carci-
noid tumours of the lung a change of enolase phenotype similar to
that now reported in breast carcinoma, in contrast to colon, liver
and non-endocrine lung tumours, in which a decrease of the
expression of g-type enolase subunit was observed (Durany et al,
1997a).
Correlation of the enzyme alterations and the steroid
receptor status
BB-CK, which is a major oestrogen-regulated enzyme, has been
found to be oestrogen-responsive in experimental mammary
tumours (Kaye et al, 1981, 1986) as well as in human breast cancer
(Kaye, 1983; Scambia et al, 1986a, 1986b). However, the litera-
ture data on the correlation between the levels of CK and the ER
status of the breast neoplastic tissue is controversial. Two research
groups (Kaye et al, 1981, 1986; Lakatua and Mohammed, 1986)
reported lack of correlation between total CK activity or BB-CK
activity and the concentration of either ER or PR in human breast
tumour samples. Scambia et al (1986b) found total CK activity to
be significantly higher in ER-positive/PR-positive and ER-
negative/PR-positive tumours, although no correlation was found
between ER or PR content and total CK or BB-CK activity. The
same group in a second report (Scambia et al, 1988) showed a
positive relationship between BB-CK positivity and ER content in
ER-rich breast tumours. Winstend and Hopps (1995) reported
correlation between high levels of total CK activity and positive
ER levels. Zarghami et al (1995, 1996) reported association
between BB-CK and ER but not PR, although in only one of the
reports (Zarghami et al, 1995) did this association reach statistical
significance.
As shown in Table 7, our results indicate no correlation between
total CK activity and the ER-positive or PR-positive status of the
breast tumours. Discrepancies in the reported data on correlation
between enzymatic activity and steroid receptor status of breast
carcinomas do not only exist in the case of CK (Messeri et al,
1983, and references therein). They could derive from the different
number of patients studied and from the different methods used to
assay the receptors (Zarghami et al, 1996) and the enzyme activity
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Figure 3 Electrophoretograms of enolase isoenzymes in extracts of human breast normal tissue and carcinomas. Lane 1, brain; lanes 2 and 3, case no. 1;
lanes 4 and 5, case no. 2; lanes 6 and 7, case no. 3; lanes 8 and 9, case no. 9, lanes 10 and 11, case no. 12; lanes 12 and 13, case no. 6. Even lines, tumour
tissue; uneven lines, normal tissue. Experimental conditions were those described in Material and Methods26 N Durany et al
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(Messeri et al, 1983). An additional factor of discrepancy could be
the great intratumoural heterogeneity existent in breast neoplastic
tissue. Immunohistochemical localization of BB-CK have demon-
strated the frequent presence of positive and negative cells in close
proximity (Scambia et al, 1988). Biochemical determination of the
activities and of the isoenzyme patterns of several glycolytic
enzymes have shown regional heterogeneity (Hennipman et al,
1988). Heterogeneity has been reported also in receptor status of
breast tumours (Klinga et al, 1982; Osborne, 1985; Pertschuk et al,
1985).
PGM has not been proved to be regulated by steroid hormones.
However, as summarized in Table 7, a correlation appears to exist
between the total PGM activity and the steroid receptor status of
the breast carcinomas. The ER-negative/PR-negative carcinomas
possess significantly higher PGM activity than the ER-
positive/PR-positive tumours.
The mean value of total enolase activity of ER-negative/PR-
negative breast carcinomas is higher than that of ER-positive/PR-
positive breast tumours, although the difference between both
groups of tumours only reach statistical significance when the
activity is expressed a function of the extracted protein (Table 7). It
is known that the majority of tumours possessing NSE have
immunoreactivity for several hormone receptors. Among the
breast tumours, it was found that NSE-positive carcinomas were
more frequently ER-positive than the NSE-negative ones, and that
the ER levels were higher in the NSE-positive samples (Nesland et
al, 1985; Erikstein et al, 1988). Although the number of tumours
studied by us is small, our results agree with this finding. As
shown in Table 6, four out of the five ER-positive/PR-positive
tumours (cases 1, 2, 3, 11 and 12) are included in the group of
tumours with higher proportion of NSE.
As indicated above (Table 4), in contrast to the PGM and the
enolase activity, the 2-phosphoglycolate-stimulated BPGP activity
in breast carcinomas is lower than in the corresponding normal
breast tissue. When the steroid receptor status of the tumour
samples is considered (Table 7), it is evident than only the ER-
negative/PR-negative group of carcinomas possesses statistically
significant lower BPGP activity than the group of normal tissues.
CONCLUSION
It is concluded that PGM, enolase, CK and BPGP activities are
differently affected in breast carcinomas. Whereas the PGM,
enolase and CK activities increase in tumours, the BPGP activity
decreases. A correlation appears to exist between the steroid
receptor status of the carcinomas and the changes of PGM, enolase
and BPGP activities. These three enzymatic activities present
greater changes in the ER-negative/PR-negative carcinomas than
in the ER-positive/PR-positive tumours. No correlation has been
found between the receptor status of the carcinomas and the levels
of CK activity.
Tumoural breast tissue shows minor changes in the PGM and
enolase isozyme patterns. In the PGM phenotype we have detected
a decrease in the expression of M-type subunit, which is typical of
differentiated muscle and sperm cells, and which is present in very
low levels in normal breast tissue. In the enolase phenotype we
have observed some increase of the isoenzymes possessing g-type
subunit, which is mainly expressed in nervous tissue and in
neuroendocrine cells. No change has been observed in CK pheno-
type. None of the changes detected in breast tumours is great
enough to be used as good breast tumour marker.
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